[轉載]随着新冠病毒在疫苗接种率高的国家飙升，中国的疫苗受到审查
(中文採用google翻譯，字詞轉換可能會出錯，我沒檢查，請以原文為準)
https://www.forbes.com/sites/roberthart/2021/06/17/chinas-sinovac-vaccine-under-scrutiny-as-covid-soars-in-highly-vaccinated-countries/?sh=6690cd4e1444
罗伯特·哈特 福布斯员工
背线 对中国华兴疫苗有效性的担忧持续增加——印度尼西亚报告称，在接种疫苗的医疗专业人员中爆发了数百起疫苗，受灾严重的哥斯达黎加拒绝使用它，因为担心它不起作用——中国全球疫苗接种的最新绊脚石随着部署其两种旗舰疫苗的大量接种疫苗的国家面临世界上最严重的疫情爆发。
关键事实
官员周四表示，尽管大多数医护人员已接种了科维德疫苗，但在印度尼西亚仍有超过 350 名医生和医疗专业人员感染了 Covid-19 ，而就在官员称赞该疫苗在卫生工作者中消灭这种疾病后仅一个多月。
官员补充说，其中数十人住院治疗，这导致专家质疑中国注射疫苗的有效性，尤其是针对助长该国爆发的传染性三角洲变种。
周三，哥斯达黎加正处于严重的 Covid-19 爆发中，在卫生官员检查临床数据后认为它不够有效后，拒绝交付Sinovac疫苗。
这些事件加剧了人们对中国制造疫苗有效性的日益担忧，因为猛烈的疫情席卷了一些接种疫苗最多的国家，其中许多国家严重依赖中国的旗舰国药和科兴疫苗进行接种活动。
虽然这两种疫苗都获得了世界卫生组织的紧急授权，但科兴的 51%功效仅略高于世界卫生组织对 Covid-19 疫苗的 50% 功效阈值，而且缺乏公开临床数据来支持制造商经常不一致的声明阻碍了公众的接受的疫苗。
科兴未回应《福布斯》的置评请求。
反对派
乌拉圭在周二首次发布了有关科兴新药效力的真实世界数据时表示，该疫苗在预防 ICU 入院和死亡方面的有效性超过 90%，预防感染的有效性为 61%。尽管接种疫苗的人数几乎比任何其他国家都多（它已为超过60% 的人口接种了至少一针，高于美国），但乌拉圭正在应对世界上 Covid-19 死亡率最高的国家之一。中国制药公司很少解决公众对疗效的担忧，中国官员表示，对其疫苗的质疑是反华偏见和选择性报道的一个例子。中国外交部发言人华春莹表示，华尔街日报 一篇质疑疫苗在塞舌尔疫苗接种率高的疫情中的作用的文章“暴露了他们处处诋毁中国的不健康心态”。
关键背景
在大流行期间，中国将其疫苗作为其外交政策武器库中的关键武器，经常将其分发给无法获得其他疫苗和愿意支付的其他国家的较贫穷国家。对于某些国家（例如匈牙利）而言，价格似乎使它们成为世界上最昂贵的国家之一。中国坚决捍卫其疫苗的质量，在完成后期临床试验之前很久就推出了疫苗，尽管它广泛避免在同行评审的期刊西方制造商上发表临床试验数据的做法（国药最终做到了，并指出该试验可能不是“测试慢性病患者、妇女和（和）老年人的疗效”）。
我们不知道的事
由于没有可用数据，Sinovac 对新的 Covid-19 变体的有效性尚不清楚。什么是已知的其他疫苗对变异三角洲是保护显着下降，只有一个剂量和更有限的下降，一旦完全免疫。即便是疗效的小幅下降，也会使科兴的目标低于世卫组织的门槛。
重要报价
中国疾病预防控制中心主任乔治·高在 4 月的一次会议上承认中国疫苗效力不佳，这似乎是党内无意间的异议。高说，国家正在探索“解决现有疫苗效力不高的问题”的方法。中国迅速驳斥了国内和国际舞台上对高的评论的看法，在社交媒体上发表评论并公开谴责该声明。在官方媒体上，高后来将这一事件描述为“误会”。
进一步阅读
数百名接种疫苗的印度尼西亚卫生工作者感染了 COVID-19，数十人住院（路透社）
一些疫苗接种率最高的国家正面临 Covid 死亡和感染的激增——专家称自满是部分原因（福布斯）
Covid 在 5 个接种疫苗最多的国家中的 4 个国家激增——这就是美国应该担心的原因（福布斯）
哥斯达黎加拒绝交付 Sinovac COVID-19 疫苗，称其不够有效（路透社）
对中国的国药 Covid 射击的担忧加剧：巴林计划为完全接种疫苗的人提供辉瑞助推器（福布斯）
*******************************************
EDITORS' PICK | Jun 17, 2021, 01:20pm EDT
China’s Sinovac Vaccine Under Scrutiny As Covid Soars In Highly Vaccinated Countries
TOPLINE Concerns over the effectiveness of China’s Sinovac vaccine continue to grow—Indonesia reported hundreds of outbreaks among medical professionals who took the vaccine and hard-hit Costa Rica declined to use it for fear it won’t work—the latest stumbling block for China’s global vaccination drive as heavily vaccinated countries deploying its two flagship vaccines face some of the world’s worst outbreaks.
KEY FACTS
More than 350 doctors and medical professionals have contracted Covid-19 in Indonesia despite the majority of healthcare workers having been immunized with Sinovac, officials said Thursday, just over a month after officials praised the shot for wiping out the disease among health workers.
Dozens of these were hospitalized, officials added, leading experts to question the effectiveness of the Chinese shot, particularly against the infectious Delta variant fueling the country’s outbreak.
On Wednesday, Costa Rica, in the midst of a severe Covid-19 outbreak, rejected a delivery of the Sinovac vaccine after health officials, examining clinical data, decided it was not effective enough.
These incidents add to growing concerns surrounding the efficacy of Chinese-made vaccines as fierce outbreaks tear through some of the most vaccinated nations, many of which relied heavily on China’s flagship Sinopharm and Sinovac vaccines for inoculation campaigns.
While both vaccines have been granted emergency authorization by the World Health Organization, Sinovac’s 51% efficacy only just exceeds the WHO’s 50% efficacy threshold for Covid-19 vaccines and a lack of public clinical data to back up manufacturers’ often inconsistent claims hampers public acceptance of the vaccine.
Sinovac did not respond to Forbes’ request for comment.
CONTRA
Uruguay, in the first release of real world data on Sinovac’s efficacy Tuesday, said the vaccine was over 90% effective at preventing ICU admissions and deaths, as well as 61% effective at preventing infections. Despite having vaccinated more people than almost any other country (it has given over 60% of its population at least one shot, higher than the U.S.), Uruguay is dealing with one of the highest Covid-19 death rates in the world. The Chinese pharmaceutical companies rarely address public concerns over efficacy and Chinese officials say questions over its vaccines are an example of anti-China bias and selective reporting. Chinese Foreign Ministry spokesperson Hua Chunying said a Wall Street Journal article questioning the role of the vaccines in the highly vaccinated Seychelles outbreak “exposes their unhealthy mind-set of denigrating China at every turn.”
KEY BACKGROUND
China has made its vaccines a key weapon in its foreign policy arsenal during the pandemic, often distributing them to poorer nations unable to access other vaccines and others willing to pay. For some countries, like Hungary, the price appears to place them among the most expensive in the world. China staunchly defends the quality of its vaccines, which it rolled out long before completing late stage clinical trials, though has broadly eschewed the practice of publishing clinical trial data in peer reviewed journals Western manufacturers (Sinopharm eventually did, where it was noted the trial could not “test the efficacy among those with chronic diseases, women, (and) older adults”).
WHAT WE DON’T KNOW
With no data available, the effectiveness of Sinovac against new Covid-19 variants is unknown. What is known of other vaccines against the Delta variant is a marked drop in protection with only one dose and a more limited drop once fully immunized. Even a small drop in efficacy would take Sinovac’s shot below the WHO threshold.
CRUCIAL QUOTE
George Gao, the head of the Chinese Center for Disease Control and Prevention, acknowledged the poor efficacy of China’s vaccines at a conference in April, in what seemed to be an unintentional dissent from the party line. Gao said the country was exploring ways to “solve the problem that the efficacy of the existing vaccines is not high.” China swiftly rejected the way Gao’s comments had been perceived on the domestic and international stage, flushing comments from social media and publicly rebuking the statement. On state media, Gao later described the incident as a “misunderstanding.”
FURTHER READING
Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital (Reuters)
Some Countries With The Highest Vaccination Rates Are Facing A Surge In Covid Deaths And Infections–Experts Say Complacency Is Partly To Blame (Forbes)
Covid Surges In 4 Of 5 Most Vaccinated Countries—Here’s Why The U.S. Should Worry (Forbes)
Costa Rica rejects delivery of Sinovac COVID-19 vaccine, says it is not effective enough (Reuters)
Worries Grow Over China’s Sinopharm Covid Shot: Bahrain Plans Pfizer Booster For Fully Vaccinated People (Forbes)
https://www.forbes.com/sites/roberthart/2021/06/17/chinas-sinovac-vaccine-under-scrutiny-as-covid-soars-in-highly-vaccinated-countries/?sh=6690cd4e1444
罗伯特·哈特 福布斯员工
背线 对中国华兴疫苗有效性的担忧持续增加——印度尼西亚报告称，在接种疫苗的医疗专业人员中爆发了数百起疫苗，受灾严重的哥斯达黎加拒绝使用它，因为担心它不起作用——中国全球疫苗接种的最新绊脚石随着部署其两种旗舰疫苗的大量接种疫苗的国家面临世界上最严重的疫情爆发。
关键事实
官员周四表示，尽管大多数医护人员已接种了科维德疫苗，但在印度尼西亚仍有超过 350 名医生和医疗专业人员感染了 Covid-19 ，而就在官员称赞该疫苗在卫生工作者中消灭这种疾病后仅一个多月。
官员补充说，其中数十人住院治疗，这导致专家质疑中国注射疫苗的有效性，尤其是针对助长该国爆发的传染性三角洲变种。
周三，哥斯达黎加正处于严重的 Covid-19 爆发中，在卫生官员检查临床数据后认为它不够有效后，拒绝交付Sinovac疫苗。
这些事件加剧了人们对中国制造疫苗有效性的日益担忧，因为猛烈的疫情席卷了一些接种疫苗最多的国家，其中许多国家严重依赖中国的旗舰国药和科兴疫苗进行接种活动。
虽然这两种疫苗都获得了世界卫生组织的紧急授权，但科兴的 51%功效仅略高于世界卫生组织对 Covid-19 疫苗的 50% 功效阈值，而且缺乏公开临床数据来支持制造商经常不一致的声明阻碍了公众的接受的疫苗。
科兴未回应《福布斯》的置评请求。
反对派
乌拉圭在周二首次发布了有关科兴新药效力的真实世界数据时表示，该疫苗在预防 ICU 入院和死亡方面的有效性超过 90%，预防感染的有效性为 61%。尽管接种疫苗的人数几乎比任何其他国家都多（它已为超过60% 的人口接种了至少一针，高于美国），但乌拉圭正在应对世界上 Covid-19 死亡率最高的国家之一。中国制药公司很少解决公众对疗效的担忧，中国官员表示，对其疫苗的质疑是反华偏见和选择性报道的一个例子。中国外交部发言人华春莹表示，华尔街日报 一篇质疑疫苗在塞舌尔疫苗接种率高的疫情中的作用的文章“暴露了他们处处诋毁中国的不健康心态”。
关键背景
在大流行期间，中国将其疫苗作为其外交政策武器库中的关键武器，经常将其分发给无法获得其他疫苗和愿意支付的其他国家的较贫穷国家。对于某些国家（例如匈牙利）而言，价格似乎使它们成为世界上最昂贵的国家之一。中国坚决捍卫其疫苗的质量，在完成后期临床试验之前很久就推出了疫苗，尽管它广泛避免在同行评审的期刊西方制造商上发表临床试验数据的做法（国药最终做到了，并指出该试验可能不是“测试慢性病患者、妇女和（和）老年人的疗效”）。
我们不知道的事
由于没有可用数据，Sinovac 对新的 Covid-19 变体的有效性尚不清楚。什么是已知的其他疫苗对变异三角洲是保护显着下降，只有一个剂量和更有限的下降，一旦完全免疫。即便是疗效的小幅下降，也会使科兴的目标低于世卫组织的门槛。
重要报价
中国疾病预防控制中心主任乔治·高在 4 月的一次会议上承认中国疫苗效力不佳，这似乎是党内无意间的异议。高说，国家正在探索“解决现有疫苗效力不高的问题”的方法。中国迅速驳斥了国内和国际舞台上对高的评论的看法，在社交媒体上发表评论并公开谴责该声明。在官方媒体上，高后来将这一事件描述为“误会”。
进一步阅读
数百名接种疫苗的印度尼西亚卫生工作者感染了 COVID-19，数十人住院（路透社）
一些疫苗接种率最高的国家正面临 Covid 死亡和感染的激增——专家称自满是部分原因（福布斯）
Covid 在 5 个接种疫苗最多的国家中的 4 个国家激增——这就是美国应该担心的原因（福布斯）
哥斯达黎加拒绝交付 Sinovac COVID-19 疫苗，称其不够有效（路透社）
对中国的国药 Covid 射击的担忧加剧：巴林计划为完全接种疫苗的人提供辉瑞助推器（福布斯）
*******************************************
EDITORS' PICK | Jun 17, 2021, 01:20pm EDT
China’s Sinovac Vaccine Under Scrutiny As Covid Soars In Highly Vaccinated Countries
TOPLINE Concerns over the effectiveness of China’s Sinovac vaccine continue to grow—Indonesia reported hundreds of outbreaks among medical professionals who took the vaccine and hard-hit Costa Rica declined to use it for fear it won’t work—the latest stumbling block for China’s global vaccination drive as heavily vaccinated countries deploying its two flagship vaccines face some of the world’s worst outbreaks.
KEY FACTS
More than 350 doctors and medical professionals have contracted Covid-19 in Indonesia despite the majority of healthcare workers having been immunized with Sinovac, officials said Thursday, just over a month after officials praised the shot for wiping out the disease among health workers.
Dozens of these were hospitalized, officials added, leading experts to question the effectiveness of the Chinese shot, particularly against the infectious Delta variant fueling the country’s outbreak.
On Wednesday, Costa Rica, in the midst of a severe Covid-19 outbreak, rejected a delivery of the Sinovac vaccine after health officials, examining clinical data, decided it was not effective enough.
These incidents add to growing concerns surrounding the efficacy of Chinese-made vaccines as fierce outbreaks tear through some of the most vaccinated nations, many of which relied heavily on China’s flagship Sinopharm and Sinovac vaccines for inoculation campaigns.
While both vaccines have been granted emergency authorization by the World Health Organization, Sinovac’s 51% efficacy only just exceeds the WHO’s 50% efficacy threshold for Covid-19 vaccines and a lack of public clinical data to back up manufacturers’ often inconsistent claims hampers public acceptance of the vaccine.
Sinovac did not respond to Forbes’ request for comment.
CONTRA
Uruguay, in the first release of real world data on Sinovac’s efficacy Tuesday, said the vaccine was over 90% effective at preventing ICU admissions and deaths, as well as 61% effective at preventing infections. Despite having vaccinated more people than almost any other country (it has given over 60% of its population at least one shot, higher than the U.S.), Uruguay is dealing with one of the highest Covid-19 death rates in the world. The Chinese pharmaceutical companies rarely address public concerns over efficacy and Chinese officials say questions over its vaccines are an example of anti-China bias and selective reporting. Chinese Foreign Ministry spokesperson Hua Chunying said a Wall Street Journal article questioning the role of the vaccines in the highly vaccinated Seychelles outbreak “exposes their unhealthy mind-set of denigrating China at every turn.”
KEY BACKGROUND
China has made its vaccines a key weapon in its foreign policy arsenal during the pandemic, often distributing them to poorer nations unable to access other vaccines and others willing to pay. For some countries, like Hungary, the price appears to place them among the most expensive in the world. China staunchly defends the quality of its vaccines, which it rolled out long before completing late stage clinical trials, though has broadly eschewed the practice of publishing clinical trial data in peer reviewed journals Western manufacturers (Sinopharm eventually did, where it was noted the trial could not “test the efficacy among those with chronic diseases, women, (and) older adults”).
WHAT WE DON’T KNOW
With no data available, the effectiveness of Sinovac against new Covid-19 variants is unknown. What is known of other vaccines against the Delta variant is a marked drop in protection with only one dose and a more limited drop once fully immunized. Even a small drop in efficacy would take Sinovac’s shot below the WHO threshold.
CRUCIAL QUOTE
George Gao, the head of the Chinese Center for Disease Control and Prevention, acknowledged the poor efficacy of China’s vaccines at a conference in April, in what seemed to be an unintentional dissent from the party line. Gao said the country was exploring ways to “solve the problem that the efficacy of the existing vaccines is not high.” China swiftly rejected the way Gao’s comments had been perceived on the domestic and international stage, flushing comments from social media and publicly rebuking the statement. On state media, Gao later described the incident as a “misunderstanding.”
FURTHER READING
Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital (Reuters)
Some Countries With The Highest Vaccination Rates Are Facing A Surge In Covid Deaths And Infections–Experts Say Complacency Is Partly To Blame (Forbes)
Covid Surges In 4 Of 5 Most Vaccinated Countries—Here’s Why The U.S. Should Worry (Forbes)
Costa Rica rejects delivery of Sinovac COVID-19 vaccine, says it is not effective enough (Reuters)
Worries Grow Over China’s Sinopharm Covid Shot: Bahrain Plans Pfizer Booster For Fully Vaccinated People (Forbes)
21 个评论
>> 通过打疫苗这事，我觉得大部分中国人真的就是韭菜命，还是自找的。 我列国际上的数据给他们看，打科...
“我又说，复星是江家的，也是属于你敬爱的党的，最迟9月到10月就会引进生产”
我觉得引不了啦，因为土共已经吹嘘自己全民接种完成了，引进来干什么？
